Compare Enbridge Inc (ENB) vs McKesson Corporation (MCK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs McKesson Corporation — how do they compare? Enbridge Inc trades at $56.38 (market cap $121.39B), while McKesson Corporation trades at $820.37 (market cap $93.23B). The key difference: Enbridge Inc is the larger of the two by market cap, and Enbridge Inc pays the higher dividend (5.01%). Which is the better fit depends on your goals.
| ENB | MCK | |
|---|---|---|
Market Cap | $121.39B | $93.23B |
Sector | Energy | Health |
52-Week High | $58.04 | $995.69 |
52-Week Low | $44.59 | $659.01 |
Enterprise Value | $202.19B | $97.87B |
Dividend Yield | 5.01% | 0.41% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enbridge (ENB) trades at $55.89, up 1.49% recently, with technical indicators showing a bullish trend. The company reported strong Q1 2026 earnings, beating estimates with $0.71 EPS, and maintains a robust dividend. Revenue grew to $65.19B in 2025, with net income of $7.49B, though valuation ratios like a P/E of 27.02 appear elevated relative to historical norms. Analyst sentiment is mixed with a 48% buy rating, while recent news highlights the company's $28B growth project pipeline and its positioning as a defensive, high-yield stock amid market volatility.
The outlook for ENB is balanced: growth projects and consistent cash flow support dividend sustainability, offering a defensive yield in uncertain markets. However, risks include high leverage, sensitivity to interest rates, and execution challenges on capital projects. The stock's current valuation may limit near-term upside, making it more suitable for income-focused investors rather than those seeking rapid growth.
McKesson (MCK) trades at $803.37, down 1.1% on the day, with technical indicators showing a neutral to bullish bias as the price sits near pivot point $805. The company demonstrates strong fundamental momentum with revenue growing from $264B in 2022 to $359.1B in 2025, and a consistent track record of beating earnings estimates in recent quarters. Analyst sentiment is overwhelmingly positive, with 80% recommending Buy and a consensus price target of $932.83, representing a 16% upside from current levels.
The outlook for MCK is favorable, supported by robust revenue growth, expanding profitability, and strong analyst conviction. Key opportunities include continued execution in specialty pharma and oncology services. Primary risks involve policy changes affecting healthcare distribution, intense industry competition, and execution challenges in integrating growth initiatives, which could pressure margins.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About McKesson Corporation
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →
